The company's PFA and TAVR technologies both played key roles in the successful second quarter. In addition, Medtronic expects its place in the renal denervation market to make a major impact going forward. 

Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

The WVU Heart and Vascular Institute is hosting a two-day symposium focused on exploring the benefits and long-term potential of robotic aortic valve replacement. Fans of the procedure say it represents a safe, effective alternative to TAVR and SAVR in patients with severe aortic stenosis. 

Researchers warned that “aggressive procedural modifications” should not be necessary during TAVR to mitigate the risk of prosthesis-patient mismatch. This appears to be true for patients receiving both self-expanding and balloon-expandable TAVR valves.

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm. 

Prosthesis-patient mismatch (PPM) is the phenomenon that occurs when the effective orifice area of a prosthetic heart valve isn’t adequately sized to meet a patient’s blood flow requirements. More is known today about PPM than ever before—but there is still so much to learn.